EUCTR2007-000049-36-IT进行中（未招募）不适用
Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients - ND
ITALFARMACO0 个研究点开始时间: 2007年6月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Age>=18yrs; 2) history of histologically confirmed Hodgking's Lymphoma 3) subjects are eligible for the trial if they have failed at least 1 cycle of chemotherapy with or without radiotherapy and if they are considered incurable and would be treated with second line or subsequent line salvage regimens mainly with palliative intent; 4)ANC >=1500/uL; PLT >=75000/uL; Hb >=9g/dL; bilirubin <=1.6 mg/dL; AST and ALT <=2.5 x UNL, creatinine <=2.0 mg/dL, K and Mg within normal limits; 5) measurable disease 6) ECOG performance status of 0 or 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Acitive bacterial or mycotic infection 2) a marked baseline prolongation of QTc interval > 450 msec 3) the use of concomitant medications that prolong the QTc interval 4) clinically significant cardiovascular disease 5) positive blood test for HIV, HBV and HCV 6) Identification of viral DNA by PCR for EBV, JC Virus, CMV and Herpes Zoster
研究者
相似试验
进行中（未招募）
不适用
Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy - GIVINOSTAT + Hydroxyurea in Polycythemia VeraPolycythemia VeraEUCTR2009-010982-22-ITITALFARMACO
进行中（未招募）
不适用
A phase IIA study of the histone-deacetylase inhibitor ITF2357 in patients with JAK-2 V617F positive chronic myeloproliferative diseases - NDchronic myeloproliferative diseasesMedDRA version: 6.1Level: HLTClassification code 10028578EUCTR2007-004480-21-ITITALFARMACO
进行中（未招募）
不适用
A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC) - NDEUCTR2007-007139-26-ITSENDO TECH48
进行中（未招募）
不适用
A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)EUCTR2007-007139-26-DESouthern Europe New Drug Organization (SENDO)48
进行中（未招募）
1 期
A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)SCLC is the most aggressive and lethal form of lung cancer, typically verysensitive to cytotoxic therapy when first diagnosed, but associated with ahigh incidence of tumour relapse and a very poor life expectancy. Despite the high response rate, approximately 80% of patients with limited disease and nearly all patients with extended disease develop disease relapse or progression.MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2007-007139-26-GRSouthern Europe New Drug Organization (SENDO)48